GSK plc (NYSE:GSK) Shares Sold by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC lowered its holdings in GSK plc (NYSE:GSK) by 11.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,730 shares of the pharmaceutical company’s stock after selling 3,742 shares during the period. Kavar Capital Partners Group LLC’s holdings in GSK were worth $972,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. FMR LLC grew its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK in the 2nd quarter valued at $52,487,000. Fisher Asset Management LLC increased its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its holdings in GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the period. Finally, Bridgewater Associates LP lifted its stake in GSK by 107.3% during the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after buying an additional 500,010 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of NYSE GSK opened at $34.29 on Monday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market cap of $71.06 billion, a P/E ratio of 22.26, a P/E/G ratio of 1.31 and a beta of 0.63. The business’s 50 day moving average is $33.91 and its two-hundred day moving average is $37.80.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a dividend of $0.3928 per share. This represents a $1.57 annualized dividend and a yield of 4.58%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s payout ratio is currently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.